Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?

Table 1 Clinicopathologic characteristics of patients with colorectal oligometastasis to the liver after curative liver resection

Parameters	Total (n)	With ACT (n, %)	Without ACT (n, %)	P value
Number of patients	264	200	64
Age, years
≤ 60	164	129 (64.5)	35 (54.7)	0.159
> 60	100	71 (35.5)	29 (45.3)
Sex
Male	171	128 (64.0)	43 (67.2)	0.895
Female	93	72 (36.0)	21 (32.8)
Primary tumor location
Colon	163	126 (63.0)	37 (57.8)	0.457
Rectum	101	74 (37.0)	27 (42.8)
Primary tumor differentiation
Well to moderate	206	155 (77.5)	51 (79.7)	0.713
Poor	58	45 (22.5)	13 (20.3)
T stage^a
1–3	157	122 (65.2)	35 (66.5)	0.707
4	86	65 (34.8)	21 (33.5)
N stage^b
0	103	78 (42.9)	25 (45.3)	0.814
1–2	135	104 (57.1)	31 (55.4)
Timing of metastasis
Synchronous	171	136 (68.0)	35 (54.7)	0.052
Metachronous	93	64 (32.0)	29 (45.3)
Number of metastatic tumors
1	140	102 (51.0)	38 (59.4)	0.501
2–3	99	78 (39.0)	21 (32.8)
4–5	25	20 (10.0)	5 (7.8)
Metastases diameter (cm)^c
≤ 3	173	134 (68.0)	39 (61.9)	0.371
> 3	87	63 (32.0)	24 (38.1)
Preoperative CEA (ng/mL)^d
≤ 50	200	156 (81.7)	44 (73.3)	0.161
> 50	51	35 (18.3)	16 (26.7)
Preoperative CA19-9 (U/mL)^a
≤ 35	166	128 (68.8)	38 (66.7)	0.760
> 35	77	58 (31.2)	19 (33.3)
Preoperative chemotherapy
Yes	122	98 (49.0)	24 (37.5)	0.108
No	142	102 (51.0)	40 (62.5)
MSKCC-CRS^e
0–2	162	127 (73.4)	35 (67.3)	0.390
3–5	63	46 (26.6)	17 (32.7)

ACT adjuvant chemotherapy, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, MSKCC-CRS Memorial Sloan-Kettering Cancer Center clinical risk score
^aData were available for 243 patients
^bData were available for 238 patients
^cData were available for 260 patients
^dData were available for 251 patients
^eData were available for 225 patients

ISSN: 2523-3548